You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Along with the federal settlement, the company will also pay an additional $13.2 million to settle civil claims by different state attorneys general.
The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.
The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.
Sanofi has been hit with a nearly $12 million fine for supporting a charity that covered the costs of co-pays for Medicare patients taking an expensive drug sold by the firm.
The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.
10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.
The company decided to settle the complaint in order to avoid "lengthy and distracting litigation," but denies any wrongdoing.
The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.